MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults

Nutrition Journal

Research

Yong Huo¹  Jianping Li¹  Jian Hu²  Fumin Zhang³  Yanni Wang⁴  Deming Guan⁵  Junbo Ge⁶  Zhigang Zhao⁷  Zeyuan Liu⁸  Yimin Cui⁹  Xin Xu^1,10  Xiping Xu^1,11  Xianhui Qin^1,11  Xiaobin Wang^1,12 

[1] Department of Cardiology and Heart Center, Peking University First Hospital, Beijing, China;Department of Cardiology, First Affiliated Hospital of China Medical University, Shenyang, China;Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China;Department of Cardiology, First Affiliated Hospital of the School of Medicine, Xi'an Jiaotong University, Xi'an, China;Department of Cardiology, First Clinical Medical College of Harbin Medical University, Harbin, China;Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China;Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;Department of Pharmacy, First Affiliated Hospital of Academy of Military Medical, Sciences of China, Beijing, China;Department of Pharmacy, Peking University First Hospital, Beijing, China;Guangdong Institute of Nephrology, Southern Medical University, Guangzhou, China;Institute of Biomedicine, Anhui Medical University, Hefei, China;Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, USA;

关键词: Folic acid supplementation;    MTHFR C677T polymorphism;    MTR A2756G polymorphism;    Homocysteine-lowering efficacy;   

DOI  :  10.1186/1475-2891-11-2

 received in 2011-08-26, accepted in 2012-01-10,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThis study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults.MethodsA total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks.ResultsAfter 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P < 0.05 for either of these genotypes) and TT genotype in the high FA group (P < 0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989).ConclusionsThis study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.

【 授权许可】

Unknown   
© Qin et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.